AF
JANX icon

Amalgamated Financial’s Janux Therapeutics JANX Stock Holding History

Amalgamated Financial’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$28K Buy
+1,928
New +$31.5K ﹤0.01% 2645

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Amalgamated Financial's JANX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Janux Therapeutics (JANX) in Q1 2022: 1,928 shares worth $28K. The stake represents ﹤0.01% of the portfolio and ranks #2645 among its holdings.

47 funds tracked by Wall St. Rank hold JANX as of Q1 2022.

  • Amalgamated Financial held 1,928 shares of Janux Therapeutics worth $28K as of Q1 2022.
  • Janux Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Janux Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2645 holding.
  • 47 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.